Autism Spectrum Disorder Trial, Recruiting NCT04936009 Sponsor: Yale University Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT04936009
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 40 years old, and either have typical brain development or have been diagnosed with autism spectrum disorder.
  • You are able to take part in brain wave (EEG) and eye-tracking tests.

Who may not be able to join:

  • You have had a serious head injury or a significant brain illness.
  • You have a major mental health condition that would make it difficult to complete the study tasks.
  • You have a history of serious medical illness, stroke, seizures, abnormal brain wave patterns, or a family history of seizures.
  • You are currently taking prescription medications that may affect thinking, memory, or other brain processes being studied.
  • You have consumed alcohol or recreational drugs in the 24 hours before the study visit.
  • You are pregnant, suspected to be pregnant, or test positive on a pregnancy test (applies to females).
  • You have a history of working with metal materials or have ever had a metal fragment or shrapnel injury to your body.
  • You have previously received TMS (a type of brain stimulation) therapy, or have taken part in a study using an experimental drug within the last 12 weeks.
  • Your IQ score is below 80.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: James McPartland, PhD, Yale University

Phone: 203-785-3488

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
17 March 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

right hemisphere N170 latency; proportion of visual attention to the eye region of the face

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov